Dose-dependent efficacy of the glucose-dependent insulinotropic polypeptide (GIP)receptor antagonistGIP(3-30)NH(2)onGIPactions in humans
Research output: Contribution to journal › Journal article › Research › peer-review
The glucose-dependent insulinotropic polypeptide (GIP) fragment GIP(3-30)NH(2)is a selective, competitive GIP receptor antagonist, and doses of 800 to 1200 pmol/kg/min inhibit GIP-induced potentiation of glucose-stimulated insulin secretion by >80% in humans. We evaluated the effects of GIP(3-30)NH(2)across a wider dose range in eight healthy men undergoing six separate and randomized 10-mmol/L hyperglycaemic clamps (A-F) with concomitant intravenous infusion of GIP (1.5 pmol/kg/min; A-E) or saline (F). Clamps A to E involved double-blinded, infusions of saline (A) and GIP(3-30)NH(2)at four rates: 2 (B), 20 (C), 200 (D) and 2000 pmol/kg/min (E), respectively. Mean plasma concentrations of glucose (A-F) and GIP (A-E) were similar. GIP-induced potentiation of glucose-stimulated insulin secretion was reduced by 44 +/- 10% and 84 +/- 10% during clamps D and E, respectively. Correspondingly, the amounts of glucose required to maintain the clamp during D and E were not different from F. GIP-induced suppression of bone resorption and increase in heart rate were lowered by clamps D and E. In conclusion, GIP(3-30)NH(2)provides extensive, dose-dependent inhibition of the GIP receptor in humans, with most pronounced effects of the doses 200 to 2000 pmol/kg/min within the tested range.
|Journal||Diabetes, Obesity and Metabolism|
|Number of pages||7|
|Publication status||E-pub ahead of print - Oct 2020|
- dose-response relationship, GIP, GIP receptor antagonist, incretin therapy, pharmacodynamics, GASTRIC-INHIBITORY POLYPEPTIDE, GIP RECEPTOR, GIP(3-30)NH2, ANTAGONIST